Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone problems news

Show

From To
People living with HIV in the UK not receiving appropriate monitoring of heart disease risk

The majority of HIV-positive people in the UK are not receiving recommended monitoring of cardiovascular risk, according to the results of an audit conducted by

Published
26 September 2017
By
Michael Carter
Bone Loss and Fracture Risk in Patients With HIV: What We Know So Far

In an interview with Infectious Disease Advisor, Todd T. Brown, MD, PhD, professor of medicine and epidemiology, division of endocrinology, diabetes, and metabolism, Johns Hopkins University, Baltimore, Maryland, discussed the effects of HIV infection and ART on BMD, as well as management strategies for HIV patients at risk for fragility fracture.

Published
11 September 2017
From
Infectious Disease Advisor
Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil, especially if combined with ritonavir, the 9th International AIDS Society Conference on HIV

Published
27 July 2017
By
Gus Cairns
Frailty is associated with loss of bone mineral density in middle-aged HIV-positive men and women

Frailty is associated with loss of bone mineral density (BMD) in HIV-positive people, investigators from France report in AIDS. They found that people living with

Published
10 July 2017
By
Michael Carter
Fractures occur at an earlier age among men with HIV

The incidence of fractures begins to rise a full decade earlier in HIV-positive men compared to their HIV-negative peers, investigators from the United States report

Published
13 June 2017
By
Michael Carter
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide

After three years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir

Published
27 March 2017
By
Liz Highleyman
Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents

TAF containing products can be made available to patients who have defined renal or bone problems or who have medical reasons why they cannot take other HIV drugs.

Published
06 March 2017
From
NHS England
High prevalence of low testosterone among younger and middle-aged ART-treated men in France

Around one in six young and middle-aged HIV-positive men doing well on antiretroviral therapy (ART) had low testosterone levels, French investigators report in the online edition of

Published
24 January 2017
By
Michael Carter
People with HIV/HCV co-infection at increased risk of kidney disease and bone disorders

Hepatitis C virus (HCV) infection in people with HIV co-infection is associated with an increased risk of liver disease and liver-related death and also several important non-liver related

Published
02 January 2017
By
Michael Carter
Co-morbidities are common and rising among people with HIV in the US

People living with HIV are increasingly experiencing a range of non-AIDS-related co-morbidities as the population ages, including cardiovascular disease, kidney impairment and bone loss leading to fractures,

Published
19 December 2016
By
Liz Highleyman
← First12345...11Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.